Article
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Targeted oncology - 1 Jun 2015
Smith Donald L, Acquaviva Jaime, Sequeira Manuel, Jimenez John-Paul, Zhang Chaohua, Sang Jim, Bates Richard C, Proia David A
Abstract excerpt
Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations. However, mechanisms to overcome the invariable development of acquired resistance to such agents, as well as realizing their full clinical potential within the context of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.